Drug intelligence / Profile preview

HEP-IV

Development stage
Unknown
Modality
Small Molecules
Administration
Intravenous, Subcutaneous
01

Overview

HEP-IV is a small molecule belonging to the dioxathiadiaza-heteropentalene class. It functions as an antimicrobial agent by inhibiting the growth of *Escherichia coli*. Its mechanism involves being reduced within the bacterial cell and subsequently reoxidized by molecular oxygen, a process that generates toxic reactive oxygen species, specifically superoxide (O2-) and hydrogen peroxide (H2O2). The toxicity of HEP-IV is dependent on the presence of oxygen and can be counteracted by cellular defenses such as superoxide dismutase (SOD) and catalase, which are induced by substances like yeast extract. Among its related compounds (HEP-I, HEP-II, HEP-III), HEP-IV demonstrates the highest potency in both inhibiting *E. coli* growth and inducing these protective enzymes.

Other names
1,7-dioxa-2,6-diaza-4,7 alpha lambda 4-dithia-3H, 5H-benzo[cd]pentalene-4,4-dioxide

Beyond the preview

Go deeper on HEP-IV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HEP-IV.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call